Alcon’s Tryptyr Approved by FDA for Dry Eye Disease Treatment

發(fā)布時(shí)間： 2025-05-30 閱讀：352次

分享

May 28, 2025 -- Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, for the treatment of the signs and symptoms of dry eye disease (DED). Tryptyr is a first - in - class TRPM8 receptor agonist. The neuromodulator stimulates corneal sensory nerves to increase natural tear production rapidly following instillation.

“Today marks a tremendous milestone for Alcon as Tryptyr becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care company,” David Endicott, CEO of Alcon, said in a press release. “We look forward to making this new treatment available to millions of patients affected by dry eye disease. We believe Tryptyr is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy.”

Alcon expects a US launch of Tryptyr in Q3 of 2025 and plans to expand to additional global markets in the future.